TPIRC, Translational Pulmonary and Immunology Research Center, was established in 2015 by Dr. Inderpal Randhawa. Early in his career, Dr. Randhawa dedicated his career to challenging conventional approaches to treating life-threatening food allergies, and now multiple rare diseases. This challenge involved meticulously studying vast amounts of genetic and environmental data to develop personalized, data-driven treatment plans for each patient. This multi-system approach yielded an unprecedented success rate, allowing countless food-allergic individuals, particularly children and young adults, to safely enjoy foods that were once considered dangerous. TPIRC’s success wasn’t limited to food allergies. Dr. Randhawa’s innovative model, built on precision medicine and data analysis, proved effective in tackling a wider range of complex and often rare diseases. This unique approach led TPIRC to become a safe and trustful clinic and research center for patients facing the challenges of rare and orphan diseases. TPIRC researchers are developing tools to predict lung function decline and disease progression in Cystic Fibrosis (CF) patients. This is crucial because such a decline can lead to serious complications like lung transplants. Current methods for assessing CF severity are complex and don’t predict this decline. TPIRC’s study analyzes data from patients to identify factors linked to a significant drop in lung function. Additionally, TPIRC Researchers are studying and creating treatments for Bronchopulmonary Dysplasia. Our research is looking for new ways to help by studying lung function in mice and exploring the genes involved in lung development. By understanding these areas, we hope to discover better and longer-lasting treatments for babies with BPD. We currently have 2 projects involving BPD. One measures lung function by comparing mice in an oxygen-rich environment with applied treatment to the non-manipulated control environment.